All Industries

MicroSalt revolutionises salt intake with low sodium technology and big growth plans

MicroSalt PLC

MicroSalt PLC (AIM: SALT) CEO Rick Guiney tells Proactive's Stephen Gunnion that the recently listed company specialises in innovative food technology that enhances the flavour of salt with significantly less sodium through patented technology. This technology changes the salt crystal's size, increasing its surface area for a fuller flavour without excess sodium intake, a major global health concern. The company targets food manufacturers, offering a product with the same functionality as traditional salt but processed differently. Additionally, MicroSalt aims to enter consumer markets, with products already available on Amazon in the UK and in about 500 stores in the US. MicroSalt's technology is distinguished by an exclusive patent, marking a significant advancement in efforts to reduce sodium consumption over the past two decades. The company's strategy includes expanding into the UK retail market, engaging with major supermarket groups to offer MicroSalt on shelves and incorporate it into their own brands, aiming for products like crisps to retain their taste while having 50% less sodium. The decision to list on the AIM market reflects London's receptivity to small food technology firms and its strategic importance in the food and ingredients sector. MicroSalt's IPO aims to raise public awareness about its low-sodium solution and the broader health issues related to sodium intake. Regulatory support for low sodium initiatives is significant, with governments recognizing the health and economic benefits of reducing sodium consumption. MicroSalt has also announced an export collaboration with American Trading International (ATI), facilitating access to 90 markets through ATI's distribution network, and enhancing the company's growth prospects. Looking ahead, MicroSalt anticipates significant developments in 2024 and 2025 as it expands its reach to consumers and large food manufacturers. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

March 04, 2024 08:47 AM Eastern Standard Time

Video

News Release

Voyageur Pharmaceuticals and API Forge Alliance for Carbon-Based Imaging Drug Advancement

Voyageur Pharmaceuticals Ltd.

Calgary, Canada – TheNewswire - March 4, 2024 - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the "Corporation") and Applied Pharmaceutical Innovation (API), a leading industry-funded not-for-profit organization driving life sciences commercialization, proudly announce the signing of a Master Services Agreement ( MSA ). This collaboration represents a significant advancement in both entities’ commitment to innovation, heralding a transformative step forward for Canada’s thriving life sciences sector. Under this strategic agreement, API will play a crucial role in accelerating Voyageur’s imaging contrast medium product development, manufacturing, and commercialization. Leveraging API’s scientific and pharmaceutical expertise, the collaboration aims to facilitate regulatory approvals and expedite the market entry of Voyageur’s contrast imaging products. This partnership will strategically target FDA, Health Canada and other regulatory agencies, by licensing across several key development areas: Accelerating the development and registration of the innovative V@C60 MRI drug (Vanadium Fullerene Molecule for magnetic resonance imaging https://voyageurpharmaceuticals.ca/voyageur-pharmaceuticals-ltd-and-rain-cage-carbon-inc-announce-breakthrough-in-imaging-technology-with-vanadium-fullerene-molecule/ Developing novel fullerene imaging products for targeted drug delivery within the body, with a focus on applications in Oncology. Introducing an advanced suite of new barium contrast media products, with the goal to displace current products in the market. Expanding Voyageur’s Iodine contrast media product pipeline, including potential development of fullerene iodine products Developing a carbon 60 based nutraceutical health supplement "We are thrilled to embark on this groundbreaking collaboration with Voyageur, advancing healthcare through the commercialization of mineral-based active pharmaceutical ingredients for the medical imaging market," stated Andrew MacIsaac, CEO at API. "This partnership underscores our commitment to driving innovation and elevating the life sciences landscape in Canada and globally." Brent Willis, CEO of Voyageur, expressed excitement about the collaboration, stating, "Our vision is to become the world's first company capable of creating new carbon-based drugs from captured CO 2, ensuring carbon-neutral pharmaceuticals. This strategic alliance with API will accelerate Voyageur's development programs, with a primary focus on creating a groundbreaking carbon-based MRI drug and advancing our iodine contrast media product pipeline." By amalgamating API's regulatory expertise with Voyageur's research and development capabilities, this partnership is poised to showcase global leadership in pharmaceutical development. The collaboration exemplifies how the intersection of Alberta's strengths in natural resources, scientific innovation, and environmental stewardship can result in enhanced healthcare solutions worldwide. Together, API and Voyageur aim to streamline the integration of Voyageur’s contrast media products, reducing supply chain risks and aiding healthcare practitioners in diagnosing diseases, disorders, and abnormalities globally. About Voyageur Pharmaceuticals Ltd.: Voyageur (TSX Venture Exchange: VM) is a Canadian public company at the forefront of barium, iodine, and carbon Active Pharmaceutical Ingredients (API) and high-performance, cost-effective imaging contrast agents. Focused on vertically integrating the barium, iodine, and carbon contrast imaging market, Voyageur aims to become a key player by producing its own minerals. Committed to sustainability, Voyageur envisions a future of carbon neutrality. Utilising Rain Cage Carbon Inc patented Eden System, Voyageur plans to capture carbon producing an added revenue stream to help finance operations and create the carbon used for new drug development. The Corporation holds a 100% interest in the Frances Creek property, a NI-43-101 barium sulfate (barite) project with an assigned $344M NPV based on a 2021 preliminary economic assessment. Voyageur is building vertical integrated product lines that are all 100% carbon neutral. About API: API stands as one of Canada's largest life sciences commercialization organizations, dedicated to enhancing the quality-of-life sciences. As an industry-funded not-for-profit, API provides end-to-end support to life sciences researchers, businesses, and innovators on their journey from idea to commercialization. With scientific leadership from Nobel Laureate Sir Michael Houghton, API provides access to facilities and experts that help pharmaceutical projects reach the market. With a commitment to sharing expertise, resources, and infrastructure, API aims to build an unparalleled life sciences sector driving prosperity for all. For media inquiries, please contact: Voyageur Pharmaceuticals Ltd. API (Applied Pharmaceutical Innovation) Tessa Vriend, Director, Engagement & Brand tessa.vriend@appliedpharma.ca Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Cautionary Statement Regarding “Forward-Looking” Information. This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to the perceived benefits to Voyageur from entering into the MSA; Voyageur’s expectations and timing with respect to developing pharmaceutical drugs including the Va@C60 MRI drug, fullerene imaging drugs, new barium contrast drugs, iodine contrast and fullerene iodine drugs, and nutraceutical health supplements; Voyageur’s perceived costs and other benefits from its collaboration with API; Voyageur’s anticipated plans and benefits from its relationship with API; Voyageur’s expectation that it will be able to secure the financing necessary to pursue its objectives; and other statements herein, which expressly or impliedly speak to Voyageur’s expectations for its business and operations. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties, including, without limitation, global market factors and supply chain issues, risks relating to the regulation and approval of Voyageur’s products, and general risks relating to Voyageur’s business. There can be no assurance that such information will prove to be accurate and actual.

March 04, 2024 08:30 AM Eastern Standard Time

Knightscope (NASDAQ: KSCP) Demonstrates The Value In Its Autonomous Security Robots As Clients Continue To Renew Recurring Revenue Contracts

Benzinga

By Faith Ashmore, Benzinga Robots are taking over headlines in 2024 as the world continues to advance and companies around the globe showcase innovative ways to incorporate robots into our society. The robotics market was valued at $31.38 billion in 2021 and is expected to reach $110.39 billion by 2030, with a CAGR of 15% from 2022-2030. One company that is demonstrating how robotics can be integral to public safety is Knightscope (NASDAQ: KSCP), a technology company ushering in the dawn of Autonomous Security Robots (ASRs). Knightscope’s success has garnered attention across the nation, and the company has won corporate contracts with major corporations, law enforcement agencies and even the U.S. Federal Government. These clients are among a long list of other collaborations. However, one of the most impressive aspects of these partnerships is how many continue to re-sign with Knightscope – the company reports that several re-sign for 3, 4, 5, 6, 7 and even 8 consecutive years. This is a key proof point in the company’s claim of “recurring revenue for the recurring societal problem of crime.” In February, the company announced the renewal of its K5 ASR contract with a long-standing client in the entertainment industry. This renewal marks the eighth consecutive year of collaboration between the client – who is based in North Hollywood – and Knightscope. Knightscope reports that the client has consistently expressed satisfaction with the ASRs' ability to deter security threats, making it a top priority in their quarterly business reviews. Before the deployment of the ASRs, the client faced issues such as trespassing, vandalism, theft and break-ins. However, over the past seven years, these incidents have been significantly reduced to only a few isolated cases. A Las Vegas apartment complex has also recently renewed its contract for the K5 ASR for the fourth consecutive year. The success of this deployment was previously covered by the Las Vegas Review-Journal and News 3 Las Vegas, highlighting the company's ability to maintain a dedicated customer base, reduce acquisition expenses and provide cost-efficient solutions in order to positively impact its financial outlook. Starting from February 28, 2024, Knightscope will be participating in multiple events throughout Las Vegas. The first one is the World Game Protection Conference at the Tropicana. On March 18, 2024, EVP and Chief Client Officer Stacy Stephens will return to Mandalay Bay for Shoptalk. Stephens will be a panelist for the session titled “Enhancing Store Performance, Security and Safety.” Another event in April is also in the pipeline and will be announced at a later date. Contract renewals are not just routine procedures; they exemplify Knightscope's capacity to foster growth, stability and strengthened partnerships with existing clients. In January, a Fortune 500 company located in Charlotte, NC renewed its contract with Knightscope for a third year. Since 2022, the finance company has chosen to utilize the K5 ASR for patrolling a recently built parking structure. These ongoing renewals not only validate the company's Machine-as-a-Service (MaaS) business model but also generate recurring revenue that contributes towards solving a persistent societal issue. While the company is always looking for new business, consistent and recurring partnerships serve to highlight trust and satisfaction in Knightscope's products and business model. These renewals also provide valuable opportunities to nurture relationships and better understand evolving client needs, as well as the potential for recommendations or the expansion of business opportunities – all while reducing costs and making the world safer. Click here to read more about the company’s future plans from CEO William Santana Li Featured photo courtesy of Knightscope. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT IS AVAILABLE HERE. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

March 04, 2024 08:30 AM Eastern Standard Time

Image

No More Jitters? Company Says Its Hydro-CaffeineTM Improves Your Morning Caffeine Fix’s Benefits By 400-500%

Rexis Biotech

By Meg Flippin, Benzinga It’s no secret that many people turn to chugging caffeine-induced drinks to get them through the day. But what they may not realize is too much caffeine can be a bad thing. Jitters, elevated heart rates and anxiety are just some of the side effects many consumers just learn to accept. But caffeine overload doesn’t have to be the foregone conclusion just to get your caffeine fix. Products like Rexis Biotech Inc.’s Hydro-Caffeine TM are revolutionizing the energy drink market. Thanks to its nanotechnology, the Delaware biotech firm says it has created a better caffeine that gives you energy without all the bad side effects. Quadruple The Effects For Less Hydro-Caffeine can be found in Rexis’s new groundbreaking energy drink Squared Energy, a product line extension to their already successful Squared brand which is available in over 2,000+ retailers in 10 states across the country. It is created using the company’s proprietary co-crystal that amplifies the effects by increasing the bioavailability of its caffeine co-crystal by four to five times. Rexis is taking it up a level with this drink by fusing Hydro-Caffeine with naturally occurring Hemp Delta-9 THC + broad-spectrum CBD to create a singular polymorph molecule in which all three work together for the ultimate entourage effect. That creates a unique experience for consumers highlighted by clear-headed, focused energy without any jitters or anxiety, according to Rexis. The first two flavors they’ll be bringing to market include a Raspberry Lemonade and their High Spirits Awards-winning Sparkling Grapefruit. Hydro-Caffeine could be a huge winner for both consumers and Rexis shareholders; caffeine is a very popular energy stimulant. Not only does caffeine give you energy but it can reduce the risk of cardiovascular disease and type 2 diabetes and improve longevity, which is why caffeine is so popular in the U.S. and abroad. While coffee and tea are the most common ways to get a caffeine fix, energy drinks, caffeine pills and supplements are also popular. In fact, the global energy drinks market is poised to reach $108.4 billion by 2031, growing at a CAGR of 8.2% from 2022 to 2031. In the U.S. 93% of Americans say they consume caffeine, with 75% partaking in it daily, according to the International Food Information Council. One-quarter of that group consumes caffeine three or more times a day. It is the latter group that worries doctors. Caffeine overdose is real and can lead to several issues including insomnia, jitters, anxiety, elevated heart rate and headaches. It tends to happen a lot since many Americans underestimate the safe amount of caffeine to consume and still remain healthy. Worse, the International Food Information Council found nearly 29% of consumers in the U.S. say they don’t know what the safe amount of caffeine is. The Secret Sauce Rexis says that with Squared Energy, you need not worry about getting too much or too little caffeine to reap the benefits. The secret behind it is the Hydro-Caffeine fibers which are absorbed more efficiently and rapidly through sublingual and buccal absorption in the cheeks and mouth. That differs from traditional energy drinks, which use a form of encapsulated caffeine in which the caffeine is coated with a sugar-type substance to eliminate bitter flavors. That process increases the time it takes to absorb, decreasing the portion introduced into circulation. The caffeine then must be processed by first-pass metabolism, which reduces efficacy even more. As a result, Rexis says you may receive as much as 25% less of the ingredient in your system than what is said on the packaging. “Shaking Up” The Market Rexis’s potentially game-changing Squared Energy drink isn’t the only way the biotech is shaking up the consumer markets. With its proprietary nanotechnology, it can improve the potency, taste and speed of effectiveness in everything from energy drinks to cannabis-infused beverages. The goal of Rexis Biotech is to be the Nvidia Corp. (NASDAQ: NVDA) or Intel Corp. (NASDAQ: INTC) of the consumer packaged goods industry. It envisions a world where brands license Rexis’s nanotechnology to enhance everything from drinks to food. To meet that end Rexis also manufactures and distributes products for companies including Hemp D9 beverages for 3Chi and functional mushrooms for First Person. It also licenses its technology to brands in the regulated cannabis market including Smokiez and Happy Valley. Caffeine will always be a preferred way to get a boost, but that doesn’t mean consumers have to accept the negative side effects. Jitters, headaches and elevated heart rates could become a thing of the past thanks to Rexis Biotech. Rexis Biotech is currently raising funds to support its growth. Click here to learn more about Rexis Biotech’s crowdfunding raise, and how to invest in the company the founders are modeling after Nvidia! Featured photo by Mark Daynes on Unsplash. Rexis is the industry leader and pioneer in developing Hydrophobic Molecule Delivery systems. Leading in the innovation, production and formulation of water based ingredients for use in the Pharmaceutical and Consumer Packaged goods industry. Established in 2022, Rexis is building a core mix of proprietary IP used to sustain strong sales models with pharmaceutical licensees, consumer packaged goods manufacturers and clinical research teams. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Ryan Erving ryan@rexissystems.com Company Website https://www.rexissystems.com

March 04, 2024 08:25 AM Eastern Standard Time

Image

News Release

Enhanced Design Breakthrough Makes Ventripoint's VMS+ Even Simpler to Use

Ventripoint Diagnostics Ltd.

***Faster, User Friendly Cardio AI Imaging Product for Commercial Roll Out*** Toronto, Ont. — TheNewswire --- March 04, 2024 — Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT ); ( OTC:VPTDF) released a significant upgrade to the design and function of its whole-heart analysis system (VMS+3.2), which accelerates imaging, analysis and ease of use at the point of care. The new design allows immediate calibration by technicians with existing ultrasound equipment to more quickly generate 2D ultrasound images, which the VMS+3.2 turns into a high-definition 3D heart model. The upgraded system also includes an improved 3D visualization tool, which speeds up and facilitates the analysis of 3D ultrasound exams. VMS+3.2 release improves the ease-of-use of 2D and 3D echocardiogram procedures for sonographers, cardiologists and caregivers, assuring seamless integration of Ventripoint technology into patient-care workflow and standard of care. In a busy echocardiography unit, reducing the time for a procedure without compromising the quality of the results is a constant challenge and the VMS+3.2 will be appreciated for these innovations. “We are constantly improving the design of our system, to generate efficiencies and better outcomes,” said Ventripoint’s Interim CEO, Hugh MacNaught. “This is a best-in-class diagnostic tool that allows enhanced echocardiograms of infants and adults to be available faster and at less cost than a cardiac MRI, with equivalent structural and functional results.” The new design removes the magnet from the probe-tracking system and so it is now immune to environments where magnetic fields are present and is no longer a concern for implanted patient medical devices, such as pacemakers and other cardiac devices, where magnets can be disruptive. The Company intends to submit to regulatory agencies for the removal of this limitation on the VMS+ system. Ventripoint’s technology is now being used in leading hospitals in Europe, the UK, Canada, China and the United States as an alternative to traditional MRI heart scans. These users will be offered the VMS+3.2 upgrade for a fee and future sales will be of the VMS+3.2 version. The Company is now focused on expanding the user base in hospitals and clinics worldwide. The Company has a world-class board of clinical advisors who continue to provide ideas for design improvements, which are ongoing. The company expects to announce additional enhancements in 2024, which will require regulatory approvals and enable VMS+ to be used with a wider range of patients. It is important to note that these future upgrades are software improvements, which can be seamlessly integrated into existing and new VMS+ units. For further information, please contact: Jonathan Robinson CFA JRobinson@oakhillfinancial.ca (416) 669-1001 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. About Ventripoint Diagnostics Ltd. Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada. Forward Looking Statements This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.

March 04, 2024 08:22 AM Eastern Standard Time

BestGrowthStocks.Com Issues Comprehensive Analysis of Marpai Inc

Marpai

NEW YORK, NY / NewsDirect / March 4th, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis of Marpai Inc. a health-tech company that uses AI and data to maximize healthcare outcomes. Marpai Inc (NASDAQ: MRAI) AI-based business model to lower costs while providing better healthcare options for employees and their families has piqued the interest of many investors. Best Growth Stock's full report breaks through the noise and offers an extensive comprehensive analysis of Marpai’s current and anticipated financial results, potential catalysts, share structure, cash position, and much more. Access this full analysis free: https://bestgrowthstocks.com/access-mrai-analysis/ (If you cannot click the link above, copy and paste to your browser may be required) Access this full analysis free: https://bestgrowthstocks.com/access-mrai-analysis/ (If you cannot click the link above, copy and paste to your browser may be required) About Marpai, Inc. Marpai, Inc. (Nasdaq: MRAI) is a leading, national TPA company bringing value-oriented health plan services to employers that directly pay for employee health benefits. Primarily competing in the $22 billion TPA sector serving self-funded employer health plans representing over $1 trillion in annual claims. Marpai works to deliver the healthiest member population for the health plan budget. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna and all TPA services. For more information, visit www.marpaihealth.com, the content of which is not incorporated by reference into this press release. About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions. Contact Details Best Growth Stocks Steve Macalbry Editor@bestgrowthstocks.com

March 04, 2024 07:59 AM Eastern Standard Time

Image

The New American Home® 2024

News Media Group, Inc.

Contact Details News Media Group, Inc. Karl Wayne +1 334-440-6397 karl@newsmg.com Company Website https://newsmg.com/

March 04, 2024 07:00 AM Eastern Standard Time

Video

ATFX appoints FX pioneer Drew Niv as Chief Strategy Officer

500NewsWire

London, March 4th, 2024 - ( 500NewsWire ) -- ATFX proudly announces the appointment of Drew Niv, a distinguished pioneer and thought leader in the FX industry, as its Chief Strategy Officer. With an illustrious career spanning over two decades, Drew Niv brings a wealth of experience and expertise to his new role at ATFX. Drew Niv is widely recognized for his pivotal role in co-founding FXCM in 1999 and serving as its CEO for 19 years. During his tenure, he fostered strategic partnerships with institutional clients, including major hedge funds, prominent banks, and renowned financial institutions worldwide. His visionary leadership has left an indelible mark on the FX industry, with notable contributions to groundbreaking initiatives such as the development of FastMatch in collaboration with Credit Suisse and the establishment of Grid Sight as a forerunner in Machine Learning Artificial Intelligence for analysing and predicting price movements in CFD prices. In his new capacity as Chief Strategy Officer at ATFX, Drew Niv will report directly to Joe Li, Chairman of ATFX Group. Joe Li expressed his enthusiasm for Drew Niv's appointment, stating, "We are delighted to welcome Drew Niv to the ATFX team. His extensive experience and strategic insights will be invaluable as we chart the course for our future growth and development. With Drew Niv on board, we are poised to revolutionize the landscape of financial services. His wealth of experience and strategic insights will play a crucial role in guiding our efforts to introduce groundbreaking financial products and advanced tools into the existing ATFX ecosystem. Moreover, Drew's expertise will be instrumental in forming strategic partnerships that will drive our commitment to delivering unparalleled services that cater to the dynamic requirements of individual and institutional customers globally." ATFX's commitment to innovation is evident in its track record of introducing pioneering technologies such as applying blockchain technologies in loyalty program, and AI-based solution in e-KYC workflows. These advancements reflect ATFX's proactive approach to staying at the forefront of the industry and commitment to empower traders by enhance their trading experiences. Drew Niv's appointment comes as part of ATFX's broader strategy to onboard elite professionals and expand its global footprint. Recent appointments include Linton White as Regional Head for ATFX Africa, Hormoz Faryar as Managing Director of Institutional Sales and Aditya Singh as the new Business Development Director International at ATFX MENA respectively. By recruiting highly experienced professionals like Drew Niv and fostering a culture of innovation and excellence, ATFX is poised to achieve long-term success and solidify its position as a dominant player in the global financial marketplace. About ATFX ATFX is a leading fintech broker with a global presence and licenses from regulatory authorities including the UK's FCA, Cypriot CySEC, UAE's SCA, Australian ASIC, and South African FSCA. With a strong commitment to customer satisfaction, innovative technology, and strict regulatory compliance, ATFX provides exceptional trading experiences to clients worldwide. For further information on ATFX, please visit ATFX Websites https://www.atfx.com. Contact Details ATFX sales.uk@atfx.com Company Website https://www.atfx.com/

March 04, 2024 05:00 AM Eastern Standard Time

Image

HTX DAO and HTX Ventures Attend Blockchain Festival Asia 2024: Advancing the Adoption of Innovative Crypto Technology

HTX DAO

On March 2, HTX DAO attended the Blockchain Festival Asia 2024, sponsoring both the event and the Lanyard session. This marked HTX DAO's debut at a top-tier crypto summit, highlighting its objective to enhance global recognition and attract more renowned industry institutions for its ecosystem development. HTX DAO was officially established on January 18, with the aim of being a leading decentralized autonomous organization in the blockchain ecosystem and focusing on open finance and tokenized economy. Currently, the HTX DAO ecosystem has enlisted the support of 19 major industrial players, including HTX, TRON, Poloniex, BitTorrent, Spark Digital Capital, APENFT, Stratified Capital, JustLend DAO, OIG Group, Double Peak, stUSDT, Zebec, USDD, ANKR, Sun.io, Merkle 3s Capital, WINkLink, TUSD, and Owlit Finance. HTX DAO has expressed its commitment to exploring the possibility of user autonomy within the community, facilitating information sharing across multiple channels. It aims to establish a self-governing ecosystem characterized by reciprocity and mutual benefits among platform and project teams, as well as Key Opinion Leaders (KOLs) and users. By tapping into the community's wisdom and power, HTX DAO is committed to transforming HTX into a truly people-centered exchange. Furthermore, through organizing offline community engagement activities worldwide, HTX DAO endeavors to establish direct and trustworthy connections, thereby encouraging increased participation from practitioners and institutions within the crypto industry towards the development of the HTX DAO ecosystem. During the summit, Amelia Chan, the HTX Strategic Partnerships Lead, was invited to participate in a panel discussion on the topic of "Trading on DEX vs CEX: What’s the Difference and What Are the Risks? KYC Procedures with Technology". The choice between CEX and DEX, according to Amelia, depends on various factors, such as requirements for fund control, attitude towards regulation, user experience, liquidity needs, trading preferences, and the importance placed on anonymity. In comparison, CEX offers convenience and high liquidity, while DEX ensures privacy and allows individuals to have full control over their assets, aligning closely with the decentralized principles of the cryptocurrency industry. Amelia also pointed out that HTX prioritizes user information privacy and asset security. Currently, through the implementation of advanced encryption algorithms and multi-factor authentication mechanisms, the exchange is taking all possible measures to ensure the safety of users' accounts and assets. Moreover, it provides an extensive array of user-friendly trading features and tools, empowering users to perform trades with increased precision, speed, and efficiency. Looking ahead, HTX plans to introduce even more innovative products to cater to the diverse demands of its users. It's noteworthy that HTX Ventures also participated in the summit as an exhibitor. HTX Ventures, the global investment arm of HTX, adopts a strategy of direct investment and fund investment, having invested in over 200 projects in 2023. These projects span various fields, including infrastructure, DeFi, RWA, L1 & L2 public chain ecosystems, SocialFi, NFTs, and education. Seeking to explore emerging business models within the industry, it offers comprehensive support to collaborative projects, including financing, resources, and strategic consulting, to foster the growth of the blockchain ecosystem. In an earlier statement, HTX Ventures mentioned that, in 2024, the Web3 sector is poised for deep integration, improved regulatory adaptability, and a trend towards maturity. This will facilitate the gradual implementation of interoperability between chains and ecosystems, driving the cryptocurrency market towards maturity and mainstream adoption. Moving forward, HTX and HTX Ventures are dedicated to closely monitoring the innovation and development of the Ethereum ecosystem, while continuously advancing investment and project incubation to nurture the next generation of Web3 enterprises. As per reports, the Blockchain Festival Asia 2024 took place in Singapore on March 2. The event brings together experts from various fields including blockchain technology, cryptocurrency exchanges, DeFi, NFTs, cryptocurrency mining, GameFi, and the broader fintech industry, offering a platform to explore cutting-edge industry developments and emerging trends. About HTX DAO As a multi-chain deployed decentralized autonomous organization (DAO), HTX DAO demonstrates an innovative governance approach. Unlike traditional corporate structures, it adopts a decentralized governance structure composed of a diversified group, jointly committed to the success of this organization. This unique ecosystem advocates open values and encourages all DAO participants to propose collaborations and protocol enhancements that can promote the development of HTX DAO. Contact Details HTX DAO media@htxdao.com

March 04, 2024 03:25 AM Eastern Standard Time

Image

1 ... 383 384 385 386 387 ... 3766

Back